# US 2016/0250291 A1 · Composition for preventing or treating amyotrophic lateral sclerosis using two or more isoforms of hepatocyte growth factor

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2016/0250291 A1
- Document ID: US20160250291A1
- Status: Published application
- Kind: A1
- Application number: 15/030,999
- Filed: 2014-10-22
- Published: 2016-09-01
- Earliest claimed: 2013-10-22
- Assignees: ViroMed Co., Ltd.
- Applicants: Viromed., Ltd.
- Inventors: Jae Gyun JEONG
- Web page: https://patentgrep.com/patent/US20160250291A1

## CPC

- A61K 38/1833: {Hepatocyte growth factor; Scatter factor; Tumor cytotoxic factor II}
- A61P 21/00: Drugs for disorders of the muscular or neuromuscular system
- A61P 21/02: Muscle relaxants, e.g. for tetanus or cramps
- A61P 25/28: for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
- C07K 14/4753: {Hepatocyte growth factor; Scatter factor; Tumor cytotoxic factor II}
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- C07K: PEPTIDES (peptides in foodstuffs A23; obtaining protein compositions for foodstuffs, working-up proteins for foodstuffs A23J; preparations for medicinal purposes A61K; peptides containing beta-lactam rings C07D; cyclic dipeptides not having in their molecule any other peptide link than those which form their ring, e.g. piperazine-2,5-diones, C07D; ergot alkaloids of the cyclic peptide type C07D519/02; macromolecular compounds having statistically distributed amino acid units in their molecules, i.e. when the preparation does not provide for a specific; but for a random sequence of the amino acid units, homopolyamides and block copolyamides derived from amino acids C08G69/00; macromolecular products derived from proteins C08H1/00; preparation of glue or gelatine C09H; single cell proteins, enzymes C12N; genetic engineering processes for obtaining peptides C12N15/00; compositions for measuring or testing processes involving enzymes C12Q; investigation or analysis of biological material G01N33/00)

## Abstract

The present invention relates to a composition for preventing or treating amyotrophic lateral sclerosis, the composition containing, as an active ingredient, two or more isoforms of a hepatocyte growth factor (HGF) or a polynucleotide encoding the isoforms. The composition of the present invention is used to effectively prevent or treat amyotrophic lateral sclerosis.

## Claims

### Claim 1

A pharmaceutical composition for preventing or treating amyotrophic lateral sclerosis, the composition containing, as an active ingredient, two or more isomers of hepatocyte growth factor (HGF) or a polynucleotide encoding the isomers.

### Claim 2 (depends on 1)

The composition of claim 1, wherein the two or more isoforms of HGF include full-length HGF (flHGF) and deleted variant HGF (dHGF).

### Claim 3 (depends on 2)

The composition of claim 2, wherein the full-length HGF includes the amino acid sequence of SEQ ID NO: 1, and the deleted variant HGF includes the amino acid sequence of SEQ ID NO: 2.

### Claim 4 (depends on 1)

The composition of claim 1, wherein the two or more isoforms of HGF are encoded by separate nucleotide sequences.

### Claim 5 (depends on 1)

The composition of claim 1, wherein the two or more isoforms of HGF are encoded by a single nucleotide sequence.

### Claim 6 (depends on 1)

The composition of claim 1, wherein the polynucleotide is naked DNA, or is contained in a gene delivery system.

### Claim 7 (depends on 6)

The composition of claim 6, wherein the gene delivery system is a vector.

### Claim 8 (depends on 7)

The composition of claim 7, wherein the vector is a plasmid.

### Claim 9 (depends on 8)

The composition of claim 8, wherein the vector is pCK.

### Claim 10

A method for preventing or treating amyotrophic lateral sclerosis, the method comprising administering, to a mammal, a composition containing, as an active ingredient, two or more isomers of hepatocyte growth factor (HGF) or a polynucleotide encoding the isomers.

### Claim 11 (depends on 10)

The method of claim 10, wherein the two or more isoforms of HGF include full-length HGF (flHGF) and deleted variant HGF (dHGF).

### Claim 12 (depends on 11)

The method of claim 11, wherein the full-length HGF includes the amino acid sequence of SEQ ID NO: 1, and the deleted variant HGF includes the amino acid sequence of SEQ ID NO: 2.
